FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2021 financial results on Monday, August 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET...
Eluminex Biosciences (Suzhou) Limited (Eluminex), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, announced...
FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.
FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an...
FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen's research efforts, leveraging more than 20 years...
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIRS, PSFE, TNXP, FGEN, and ABUS.
-- FibroGen Exclusively Licenses HiFiBiO's Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs
/PRNewswire/ -- The (PanCAN), a leading pancreatic cancer advocacy organization, announced today the latest update to its novel clinical trial platform, , with the addition of a new treatment arm by...
FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision Promise adaptive trial platform evaluating pamrevlumab [and standard...
Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United...
New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain...
NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...
Los Angeles, California--(Newsfile Corp. - June 11, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen,...
NEW YORK, NY / ACCESSWIRE / June 11, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders...
New York, New York--(Newsfile Corp. - June 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company")...
EQNX::TICKER_START EQNX::TICKER_END
NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders...
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action,...
